Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026
- Investors must review Exhibit 99.1 for revenue, earnings, cash flow and balance-sheet figures
- Non-GAAP results exclude acquisition-related charges, restructuring costs and selected investment and legal items
- Free cash flow defined as GAAP operating cash flow less capital expenditures, providing a liquidity view
- Adjusted metrics may improve comparability, but exclude recurring acquisition and restructuring economics
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $10.1B, up 10%, with product sales up 9% and six growth drivers up 26%, supporting continued portfolio momentum
- GAAP EPS $4.37, up 65%, while non-GAAP EPS $6.29, up 4%, reflecting higher expenses and tax pressure
- Free cash flow $3.5B versus $1.9B, strengthening liquidity despite debt rising to $57.3B from $54.6B
- 2026 guidance maintained at revenue $38.2B-$39.4B and non-GAAP EPS $22.30-$23.50
- Growth concentration risks: Prolia sales fell 32% and XGEVA 34% as biosimilars pressured volume and pricing; MariTide Phase 3 expansion remains a major pipeline catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.